Prognostic value of inflammatory markers in predicting recurrence-free survival in gastrointestinal stromal tumor patients: A nomogram-based approach

Table 5 Gastrointestinal stromal tumor patient recurrence-free survival single factor analysis of the results

Variable	n	RFS (month)	RFS (95%CI)	P value	χ2
Gender				0.697	0.152
Male	48	77.646	(69.98-85.31)
Female	76	79.395	(73.40-85.39)
Age				0.377	0.780
≤ 58	64	76.547	(69.617-83.477)
>58	60	81.033	(74.707-87.360)
BMI (kg/m2)				0.351	0.870
≤ 22	62	81.417	(75.325-87.599)
>22	62	76.188	(69.159-83.216)
Anatomic site of GIST				0.679	0.171
Stomach	76	79.513	(73.570-85.456)
Non-stomach	48	77.458	(69.699-85.218)
Targeted therapy				0.007	7.398
Yes	31	74.667	(68.756-80.577)
No	93	90.871	(86.591-95.151)
Tumor size, cm				0.604	0.269
<5	52	80.308	(73.454-87.162)
≥ 5	72	77.569	(71.125- 84.014)
SII				< 0.001	26.946
<1079	84	87.463	(83.346-91.580)
≥ 1079	42	61.643	(52.176-71.110)
NLR				< 0.001	26.845
<5.79	90	86.067	(81.817-90.316)
≥ 5.79	34	59.265	(48.708-69.821)
MLR				< 0.001	24.242
<0.430	88	86.227	(82.053-90.402)
≥ 0.430	36	60.361	(49.872, 70.851)
PLR
< 181.33	59	90	(86.172-93.828)	< 0.001	19.871
≥ 181.33	65	68.477	(60.985-75.969)

SII: Systemic immune-inflammation index; NLR: Neutrophil/lymphocyte ratio; PLR: Platelet/lymphocyte ratio; MLR: Monocyte/lymphocyte ratio; GIST: Gastrointestinal stromal tumor; BMI: Body mass index; RFS: Recurrence-free survival.